Skip to main content

Table 3 Prognostic factors by univariate and multivariate analyses

From: Does chemoradiotherapy benefit elderly patients with esophageal squamous cell cancer? A propensity-score matched analysis on multicenter data (3JECROG R-03A)

 

Pre-PSM

Post-PSM

univariate analyses

multivariate analyses

multivariate analyses

P

HR(95% CI)

P

HR(95% CI)

P

HR(95% CI)

Gender

0.184

0.886 (0.742–1.059)

    

Age

0.418

1.008 (0.989–1.028)

ECOG

0.796

1.013 (0.921–1.113)

Hypertension

0.999

1.000 (0.834–1.199)

Cardiovascular disease

0.806

1.032 (0.805–1.323)

Pulmonary disease

0.795

1.038 (0.782–1.379)

Diabetes

0.036

1.326 (1.019–1.726)

0.044

1.314 (1.007–1.714)

0.028

1.643 (1.056–2.555)

Tumor location

0.006

1.160 (1.044–1.289)

0.004

1.174 (1.052–1.311)

  

Primary tumor length

0.001

1.063 (1.024–1.102)

  

Primary tumor volume

< 0.001

1.063 (1.024–1.102)

0.026

1.003 (1.000–1.006)

Clinical T stage

0.001

1.207 (1.079–1.351)

0.028

1.146 (1.015–1.295)

0.028

1.270 (1.026–1.571)

Clinical N stage

0.001

1.351 (1.131–1.613)

0.023

1.237 (1.030–1.485)

0.001

1.673 (1.223–2.287)

Clinical M stage

< 0.001

1.825 (1.308–2.545)

0.002

1.703 (1.209–2.399)

0.001

1.965 (1.295–2.983)

GTV dose

1.398

1.000 (1.000–1.000)

    

Technique

0.676

0.964 (0.811–1.146)

Treatment pattern

0.854

1.022 (0.811–1.288)

Short-term response to RT

0.001

1.263 (1.095–1.457)

0.003

1.243 (1.076–1.435)

  1. PSM Propensity score matching
  2. ECOG Eastern Cooperative Oncology Group scoring